Reduction of Leukemia Cell Burden and Restoration of Normal Hematopoiesis at 3 Months of Crizotinib Treatment in RAN-binding Protein 2 (RANBP2)-anaplastic Lymphoma Kinase (ALK) Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 May 23

PMID 24850290

Citations 5

Authors

Y Maesako

A Okumura

K Takeoka

C Kishimori

K Izumi

Y Kamoda

F Iioka

T Akasaka

H Ohno

Affiliations

Soon will be listed here.

Citing Articles

Myeloproliferative neoplasm harboring both monosomy 7 and an fusion gene: Proposal for a new disease entity.

Yoshida H, Osone S, Konishi M, Tanaka S, Inaba T, Imamura T EJHaem. 2025; 6(1):e1071.

PMID: 39866936 PMC: 11756977. DOI: 10.1002/jha2.1071.

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.

Adashek J, Brodsky M, Levis M NPJ Precis Oncol. 2024; 8(1):197.

PMID: 39256524 PMC: 11387604. DOI: 10.1038/s41698-024-00701-y.

Hematological Neoplasms with Eosinophilia.

Morales-Camacho R, Caballero-Velazquez T, Borrero J, Bernal R, Prats-Martin C Cancers (Basel). 2024; 16(2).

PMID: 38254826 PMC: 10814743. DOI: 10.3390/cancers16020337.

Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring Intron 14 Mutation: A Case Report.

Leyrat B, Durando X, Veyssiere H, Bernadach M Onco Targets Ther. 2021; 14:3949-3958.

PMID: 34234464 PMC: 8254586. DOI: 10.2147/OTT.S312889.

The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Boulanger M, Paolillo R, Piechaczyk M, Bossis G Int J Mol Sci. 2019; 20(16).

PMID: 31405039 PMC: 6721055. DOI: 10.3390/ijms20163895.

References

Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, Okumura A . inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int J Hematol. 2013; 99(2):202-7. DOI: 10.1007/s12185-013-1482-x. View

Shaw A, Engelman J . ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31(8):1105-11. PMC: 4209068. DOI: 10.1200/JCO.2012.44.5353. View

Heuckmann J, Balke-Want H, Malchers F, Peifer M, Sos M, Koker M . Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012; 18(17):4682-90. DOI: 10.1158/1078-0432.CCR-11-3260. View

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

Raza S, TaherNazerHussain F, Patnaik M, Knudson R, Van Dyke D, Tefferi A . Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Am J Hematol. 2011; 86(4):353-6. DOI: 10.1002/ajh.21988. View

Doebele R, Pilling A, Aisner D, Kutateladze T, Le A, Weickhardt A . Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18(5):1472-82. PMC: 3311875. DOI: 10.1158/1078-0432.CCR-11-2906. View

Wass M, Behlendorf T, Schadlich B, Mottok A, Rosenwald A, Schmoll H . Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2013; 92(3):268-70. DOI: 10.1111/ejh.12240. View

Bernad R, van der Velde H, Fornerod M, Pickersgill H . Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol Cell Biol. 2004; 24(6):2373-84. PMC: 355853. DOI: 10.1128/MCB.24.6.2373-2384.2004. View

Mosse Y, Lim M, Voss S, Wilner K, Ruffner K, Laliberte J . Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14(6):472-80. PMC: 3730818. DOI: 10.1016/S1470-2045(13)70095-0. View

10.

Hallberg B, Palmer R . Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013; 13(10):685-700. DOI: 10.1038/nrc3580. View

11.

Butrynski J, DAdamo D, Hornick J, Dal Cin P, Antonescu C, Jhanwar S . Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363(18):1727-33. PMC: 3014292. DOI: 10.1056/NEJMoa1007056. View

12.

Rottgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamerdinger U, Slany R . ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia. 2010; 24(6):1197-200. DOI: 10.1038/leu.2010.18. View

13.

Ma Z, Hill D, Collins M, Morris S, Sumegi J, Zhou M . Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003; 37(1):98-105. DOI: 10.1002/gcc.10177. View

14.

Thomas R . Overcoming drug resistance in ALK-rearranged lung cancer. N Engl J Med. 2014; 370(13):1250-1. DOI: 10.1056/NEJMe1316173. View